Fabrx - Start-Up Pitch

Pharmaceutical 3D printing for personalised medicine is still a very novel field, but it is exponentially growing. The world’s first clinical study was led by FABRX in Spain in 2018. Results showed that their chewable, flavoured tablets with personalised dose had improved acceptability and bioavailability compared to standard filled capsule treatment. FABRX’s printers are now involved in more than 4 clinical trials this year, with 4 more in the pipeline. Regulatory bodies are now catching up, with the UK’s MHRA, the FDA in the US and the EMA in the European Union now all preparing regulation for point-of-care manufacturing, allowing for faster roll out of innovate solutions and breakthroughs to improve accessibility and safety of personalised medicine.